Anavex Life Sciences Corp (AVXL)

[tootalljones]

Mayomobile who posts comparative analysis here should be encourage to publish something on Seeking Alpha. He has the writing skills.

For now the market begrudges our sharp share increase. Fund managers hate the slope. And yet, our market value is little more than a piddling 1 billion dollars.
go figure...Read Mayo's comparatives for starters...

breathtaking Rett Results already released;
the same with Parkinson's results already released, a staggering market unto itself.
The advanced nature of all 3 of Anavex's major trials

Heavily credentialed scientists/doctors have not been shy about saying Avxl's RETT and PDD trials have shown EXTRAORDINARY RESULTS NEVER SEEN BEFORE.

and yet SAVA has a market cap that is laughably almost 4 times our cap.

BIIB's alzheimer's drug = ineffective, dangerous, controversial approved drug is valued in the 35+ BILLION range, perhaps a bit more.

we are all cashed up, with additional expanding drug candidates coming on line.

Dr. Missling has already turned down Offers - plural - from larger companies.
This is why you buy Anavex.

In truth, there are at this very moment other drugs that the market assigns perhaps ten million in current worth, that the future will show were worth billions. The problem is to find them. Among the thousand of candidates.

We are years ahead SAVA.
......have seen this before, where the market for whatever reasons, appears to begrudge a company, and a year or two later the stock price is up 5 fold.

The share price is a better value now than when it was at 3 bucks a share, 3 years ago. The unfairness of it all!....The word for the day is patience.
____________

From Lane Simonian's recent article dated August 21,2021
https://seekingalpha.com/article/4444436-alzheimers-drug-stock-investments

"Cassava Sciences proclaimed:

It believes the data is the first report of significant cognitive improvements at nine months that also track with robust improvements in biomarkers in patients with Alzheimer's (paraphrase).

Anavex (AVXL) issued a press release the same day as the Cassava Sciences' results in which it subtly countered this assertion by referencing the conversion of its drug's MMSE scores into ADAS-cog scores (negative ADAS-cog scores indicate improvement). The data is as follows: Anavex 2-73 (blarcamesine) produced improvements in MMSE/ADAS-cog scores of +2/-3.4 at 57 weeks and +3/-5.1 scores at 70 weeks (press release). Anavex 2-73 thus likely produces better ADAS-cog scores at 70 weeks than simufilam does at nine months. Because the range of numbers for MMSE scores is smaller than ADAS-cog scores, the average conversion factor is sometimes twice as great (3.4 rather than 1.7 times) (conversion chart, original source now behind paywall). In that case, Anavex 2-73's ADAS-cog number at 70 weeks would be 10.2. And while simufilam's numbers may still go up some more for a while, it is unlikely that they would go up by as much as another seven points.

The beneficial mechanism of action for Anavex 2-73 is probably two-fold. Anavex inhibits intracellular calcium release like Aricept but it also likely partially reverses oxidation and nitration which are key drivers of Alzheimer's disease (and probably several other neurodegenerative diseases as well). In doing so it limits mitochondrial damage and reduces neuronal cell death. If existing numbers hold up in Anavex's phase three clinical trial, Anavex 2-73 would make Alzheimer's a survivable rather than a fatal disease, with individuals having a much better quality of life."